At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 319 enrolled
Drug / intervention
LX9211 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain
In Brief
A Phase 2 clinical trial evaluating LX9211 and LX9211 Matching Placebo for Diabetic Peripheral Neuropathy and Diabetes. Completed, enrolled 319 participants across 44 sites.
Detailed Summary
Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing pain related to diabetic peripheral neuropathy (DPNP) over an 11 week assessment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Peripheral Neuropathy, Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartSep 2020
Primary CompletionMay 2022
Study CompletionJun 2022
TodayJul 2026
First PostedJul 2, 2020
Enrollment StartSep 3, 2020
Primary CompletionMay 23, 2022
Study CompletionJun 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6 years ago
Interventions
LX9211drug
Oral Tablets
LX9211 Matching Placebodrug
Oral Tablets